Search
Catumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnIts market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. … Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].
Voxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalwith an HCV regimen containing sofosbuvir without an NS5A inhibitor [L935]. … Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated
Mixtures: VOSEVİ 400 MG/ 100 MG/ 100 MG FİLM KAPLI TABLET, 28 ADETLifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalThe ophthalmic solution was approved in July, 2016 under the trade name Xiidra. … It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].
Categories: Compounds used in a research, industrial, or household settingZolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923] … [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas
DL-dimyristoylphosphatidylcholine
go.drugbank.com/drugs/DB11283ApprovedA synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. It is used in commercial drug preparations to solubilize drugs for injection [A32711]
Categories: Compounds used in a research, industrial, or household settingSynonyms: DL-dimyristoylphosphatidylcholine, Dimyristoylphosphatidylcholine, DL-Dextroamphetamine
go.drugbank.com/drugs/DB01576ApprovedIllicitInvestigationalDextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]
Mixtures: Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate ER, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate ERSynonyms: d-amphetamineAxatilimab
go.drugbank.com/drugs/DB16388ApprovedInvestigational[A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD. … Axatilimab is a humanized IgG4 monoclonal antibody produced in Chinese hamster ovary cells.
Anthralin
go.drugbank.com/drugs/DB11157ApprovedAnthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. … Anthralin has also been studied in the treatment of warts, showing promising results [A32307].
Gimeracil
go.drugbank.com/drugs/DB09257ApprovedInvestigationalThe main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … It functions by reversibly and selectively blocking the enzyme dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU [A31408].
Mixtures: TS-ONE CAPSULE 20, TS-ONE CAPSULE 20Synonyms: Ts-1 (TN)Elasomeran
go.drugbank.com/drugs/DB15654ApprovedInvestigationalat half (50 mcg) of its regular strength. … [L28026] On December 23, 2020, Health Canada issued an expedited authorization for the Moderna COVID-19 Vaccine.